X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ARINA-1 is a new nebulized product comprised of ascorbic acid, glutathione, and bicarbonate which is currently being investigated in phase 2 clinical trials for the treatment of patients with Non-cystic Fibrosis Bronchiectasis.
Lead Product(s): Ascorbic Acid,Glutathione,Bicarbonate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Arina-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2024
Details:
ARINA-1 (ascorbic acid) is an investigational nebulized therapy to prevent the progression of bronchiolitis obliterans syndrome (BOS) progression in individuals with a bilateral lung transplant.
Lead Product(s): Ascorbic Acid,Glutathione
Therapeutic Area: Immunology Product Name: ARINA-1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
ARINA-1 (ascorbic acid), an investigational nebulized therapy, to treat adults with non-CF bronchiectasis,has been shown to have significant mucolytic activity, as well as robust anti-inflammatory properties.
Lead Product(s): Ascorbic Acid,Glutathione
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ARINA-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
ARINA-1 (ascorbic acid) is a first-in-class therapy that addresses deficiencies in the innate immune system that occur in chronic inflammatory airway diseases, such as non-CF bronchiectasis, COPD, and lung transplant.
Lead Product(s): Ascorbic Acid
Therapeutic Area: Immunology Product Name: ARINA-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
ARINA-1, novel nebulized therapy delivered to the lungs to treat pulmonary diseases, it clears mucus and reduces damaging inflammation in the airways to restore lung health in non-cystic fibrosis bronchiectasis.
Lead Product(s): Ascorbic Acid
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ARINA-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
The paper provides an overview of the impact of ARINA-1 on mucus transport and shows that the ARINA-1 moves mucus significantly better than currently available options in cystic fibrosis (CF).
Lead Product(s): Ascorbic Acid,Glutathione,Bicarbonate
Therapeutic Area: Genetic Disease Product Name: ARINA-1
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Funds to be used for the development and clinical programs associated with Renovion's lead therapeutic candidate ARINA-1. ARINA-1 is a nebulized therapy developed to improve mucus clearance and decrease inflammation in patients diagnosed with chronic lung disease.
Lead Product(s): ARINA-1
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ARINA-1
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: White Rock Capital Management
Deal Size: $8.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
